#prostatecancer search results

Is blogger Dan Zeller willing to just monitor his situation and delay treatment for prostate cancer? Plus, a primer on hormone therapy. #ProstateCancer cancerhealth.com/blog/prostate-…


Hot flashes affect most men on ADT! We've lacked good options. Oxybutynin, an old drug, may change that. The NKB pathway shows us why. 🔥 @CaPsurvivorship @ASCO @JCO_ASCO @OncoAlert @OncBrothers @APCCC_Lugano #prostatecancer DOI: 10.1200/JCO-26-00144

DrYukselUrun's tweet image. Hot flashes affect most men on ADT!
We've lacked good options. Oxybutynin, an old drug, may change that. 
The NKB pathway shows us why. 🔥 @CaPsurvivorship @ASCO @JCO_ASCO @OncoAlert @OncBrothers @APCCC_Lugano #prostatecancer
DOI: 10.1200/JCO-26-00144

Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome. go.nature.com/42mnogZ

ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ
ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ
ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ

🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides 🧬 Digital path in @Nature_NPJ 🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 💊Luminal B → predicts hormone therapy response ⚠️Luminal B & LP → flags aggressive pathology at surgery ⭐️Cheaper. Faster.

Adam_Weiner535's tweet image. 🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides

🧬 Digital path in @Nature_NPJ  
🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 
💊Luminal B → predicts hormone therapy response
⚠️Luminal B & LP → flags aggressive pathology at surgery

⭐️Cheaper. Faster.
Adam_Weiner535's tweet image. 🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides

🧬 Digital path in @Nature_NPJ  
🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 
💊Luminal B → predicts hormone therapy response
⚠️Luminal B & LP → flags aggressive pathology at surgery

⭐️Cheaper. Faster.

TMPRSS2:ERG–directed radiosensitization: exploiting DNA repair rewiring in gene fusion–positive #ProstateCancer: doi.org/10.1172/JCI203… Xiaoju Wang & Arul M. Chinnaiyan @ArulChinnaiyan @UMichMedSchool provide a Commentary on Köcher et al.: doi.org/10.1172/JCI194…

jclinicalinvest's tweet image. TMPRSS2:ERG–directed radiosensitization: exploiting DNA repair rewiring in gene fusion–positive #ProstateCancer: doi.org/10.1172/JCI203…

Xiaoju Wang & Arul M. Chinnaiyan @ArulChinnaiyan @UMichMedSchool provide a Commentary on Köcher et al.: doi.org/10.1172/JCI194…

Facilitating precision therapy in #ProstateCancerdoi.org/10.1172/JCI194… Wael Y. Mansour & team @UKEHamburg discover ERG overexpression as a biomarker for identifying patients with prostate cancer who can benefit from #PARPi-based radiosensitization, enhancing radiotherapy

jclinicalinvest's tweet image. Facilitating precision therapy in #ProstateCancer… 

doi.org/10.1172/JCI194… 
Wael Y. Mansour & team @UKEHamburg discover ERG overexpression as a biomarker for identifying patients with prostate cancer who can benefit from #PARPi-based radiosensitization, enhancing radiotherapy

.@NorthwesternMed scientists have uncovered an unexpected role for a well-known cancer-related protein, revealing a new layer of genetic regulation that could reshape how certain cancers are treated. #ProstateCancer @NUFeinbergMed news.feinberg.northwestern.edu/2026/04/15/und…


Honored to have been invited to serve on @ASCO’s Metastatic Castration-Resistant Prostate Cancer Living Guideline Panel. Grateful for the opportunity to contribute to evidence-based guidance in prostate cancer care. #GUOnc #ProstateCancer #pcsm #MedTwitter #OncTwitter

KalantriShreyas's tweet image. Honored to have been invited to serve on @ASCO’s Metastatic Castration-Resistant Prostate Cancer Living Guideline Panel.

Grateful for the opportunity to contribute to evidence-based guidance in prostate cancer care.

#GUOnc #ProstateCancer #pcsm #MedTwitter #OncTwitter

🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨 @NEJM New phase 3 RCT (PATCH/STAMPEDE-1) 🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360) ✅ 87.1% vs 85.9% 3-yr MFS 🌡️ Way fewer hot flashes (44% vs 89%) 🦴

Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴

🏥 'Had minor #medical issue...': #Netanyahu says he was successfully treated for #prostatecancer 🙏 | tinyurl.com/muy8mavd


CAPTAIN Trial Results — by the numbers. This randomized trial enrolled 211 men with localized intermediate-risk #prostatecancer, comparing MRI-guided #TULSAprocedure to robotic prostatectomy. The data shows meaningful differences in recovery, function, and time back to life.

BuschCenter's tweet image. CAPTAIN Trial Results — by the numbers.

This randomized trial enrolled 211 men with localized intermediate-risk #prostatecancer, comparing MRI-guided #TULSAprocedure to robotic prostatectomy.

The data shows meaningful differences in recovery, function, and time back to life.

#prostate #prostatecancer #cancer #urology #menshealth #health #prostatehealth #kidney #urologia #prostata #men #endourology #over Beware: 3 Common Foods Linked to Prostate  Enlargement. 👇Click to learn more 👉 f.mtr.cool/bduimlxfqh 👈

WinJose8's tweet image. #prostate #prostatecancer #cancer #urology
#menshealth #health #prostatehealth #kidney
#urologia #prostata #men #endourology #over
Beware: 3 Common Foods Linked to Prostate 
Enlargement. 👇Click to learn more
👉 f.mtr.cool/bduimlxfqh 👈

#prostate #prostatecancer #cancer #urology #menshealth #health #prostatehealth #kidney #urologia #prostata #men #endourology #over Space Secrets: Astronauts' Prostate Wisdom. See how to fix👇prostate issues in the video. 👉 f.mtr.cool/tzouraqgrn 👈

trade_2022's tweet image. #prostate #prostatecancer #cancer #urology
#menshealth #health #prostatehealth #kidney
#urologia #prostata #men #endourology #over
Space Secrets: Astronauts' Prostate Wisdom.
See how to fix👇prostate issues in the video.
👉 f.mtr.cool/tzouraqgrn 👈

Don't Miss! The #APCCC26 Consensus Meeting focuses on real-world #ProstateCancer management. @Silke_Gillessen joins @neerajaiims to discuss the upcoming 10th aniversary meeting, Apr 30th - May 2nd, shaping how we manage advanced prostate cancer in the real world and tackling


🚨Focal v radical salvage therapy for radiorecurrent #prostatecancer🚨 We invited @AJWLight to discuss this 🔥 topic during #EAU26 on this episode of the #UroOncMinute @IP_London @NIHRresearch @NorthLonUrol @UrologyTimes

In this episode of The UroOnc Minute, host Adam Weiner, MD, sits down with Alexander Light, MBBS, to discuss evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer. #EAU26 Check out the full episode here: urologytimes.com/view/the-uroon…

UrologyTimes's tweet image. In this episode of The UroOnc Minute, host Adam Weiner, MD, sits down with Alexander Light, MBBS, to discuss evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer. #EAU26

Check out the full episode here: urologytimes.com/view/the-uroon…


Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. Co-authored by @AarmstrongDuke. Read the full article. bit.ly/4dXXPK7 #ProstateCancer #pcsm


📢 Great starting!! Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia

Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia

#CancerHealthStories A New Kind of Intimacy - Robert Ginyard, 57, lives in Baltimore with his wife and two children. #prostatecancer #cancer cancerhealth.com/article/new-ki…


For #ProstateCancer, there are three types 🐢🐇🐦‍⬛

Adam_Weiner535's tweet image. For #ProstateCancer, there are three types

🐢🐇🐦‍⬛

PROSTATE CANCER IS A SPECTRUM Tortoises. Rabbits. Birds. Not all prostate cancer behaves the same way. Some tumors grow very slowly and may never cause harm. These are often lower-risk cancers, commonly referred to as Gleason 6 or Grade Group 1, and many men with this type of



Is blogger Dan Zeller willing to just monitor his situation and delay treatment for prostate cancer? Plus, a primer on hormone therapy. #ProstateCancer cancerhealth.com/blog/prostate-…


ઇઝરાયલ PM નેતન્યાહુને પ્રોસ્ટેટ કેન્સર; પુરુષો માટે સાયલન્ટ ખતરો, 50 વર્ષ પછી દર વર્ષે સ્ક્રીનિંગ કરાવવું જરૂરી; લક્ષણો અને બચાવના ઉપાય - divya.bhaskar.com/cf4Z5X7KH2b #PhysicalHealth #ProstateCancer #Cancer #Health #Lifestyle

Divya_Bhaskar's tweet image. ઇઝરાયલ PM નેતન્યાહુને પ્રોસ્ટેટ કેન્સર; પુરુષો માટે સાયલન્ટ ખતરો, 50 વર્ષ પછી દર વર્ષે સ્ક્રીનિંગ કરાવવું જરૂરી; લક્ષણો અને બચાવના ઉપાય - divya.bhaskar.com/cf4Z5X7KH2b

#PhysicalHealth #ProstateCancer #Cancer #Health #Lifestyle

Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome. go.nature.com/42mnogZ

ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ
ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ
ProstateCell's tweet image. Collaborators with Drs. Strynadka, Andersen, and Sadar leveraged a library of androgen receptor (AR)-TAD inhibitors using cultured #ProstateCancer cells

Alterations in the chemical scaffold impacted selectivity and potency within the AR-transcriptome.

go.nature.com/42mnogZ

#prostate #prostatecancer #cancer #urology #menshealth #health #prostatehealth #kidney #urologia #prostata #men #endourology #over Space Secrets: Astronauts' Prostate Wisdom. See how to fix👇prostate issues in the video. 👉 f.mtr.cool/tzouraqgrn 👈

trade_2022's tweet image. #prostate #prostatecancer #cancer #urology
#menshealth #health #prostatehealth #kidney
#urologia #prostata #men #endourology #over
Space Secrets: Astronauts' Prostate Wisdom.
See how to fix👇prostate issues in the video.
👉 f.mtr.cool/tzouraqgrn 👈

👏Well deserved accolade for Rob who has contributed so much to the field of #prostatecancer @PCFnews @PCF_Science @UCLAHealthJCCC @UclaUrology

Adam_Weiner535's tweet image. 👏Well deserved accolade for Rob who has contributed so much to the field of #prostatecancer 

@PCFnews @PCF_Science @UCLAHealthJCCC @UclaUrology

We’re proud to announce the recipients of the 2026 Urology Care Foundation Research Awards of Distinction—leaders whose groundbreaking research, mentorship, and innovation are advancing urologic care and shaping the future of our field. 👏 Congratulations to all of this year’s

UrologyCareFdn's tweet image. We’re proud to announce the recipients of the 2026 Urology Care Foundation Research Awards of Distinction—leaders whose groundbreaking research, mentorship, and innovation are advancing urologic care and shaping the future of our field.

👏 Congratulations to all of this year’s


@CooperHealthNJ offers @FocalOneHIFU, the latest noninvasive, nonsurgical option in the management of prostate cancer. There is no surgery, no blood loss, and no radiation. Watch the video to learn more. #Cancer | #ProstateCancer | #Urology | #RoboticSurgery | #MedTech | #HIFU

Prostate cancer treatment doesn’t always mean surgery. At MD Anderson Cancer Center at Cooper, we offer advanced options like high-intensity ultrasound – a non-surgical treatment that targets cancer while helping patients recover faster.



#CancerHealthStories A New Kind of Intimacy - Robert Ginyard, 57, lives in Baltimore with his wife and two children. #prostatecancer #cancer cancerhealth.com/article/new-ki…


How have the PACE trials influenced radiotherapy treatment for #ProstateCancer to date? Profs Emma Hall & @nickva1 at the ICR discuss learnings from a decade of trials, including @ProstateUK-funded PACE-NODES, in @IJROBP. Grab a ☕ & read: doi.org/10.1016/j.ijro…

ProstateUKProfs's tweet image. How have the PACE trials influenced radiotherapy treatment for #ProstateCancer to date?

Profs Emma Hall & @nickva1 at the ICR discuss learnings from a decade of trials, including @ProstateUK-funded PACE-NODES, in @IJROBP.

Grab a ☕ & read: doi.org/10.1016/j.ijro…

We are delighted to be supporting the South West Urology Annual Meeting over the next couple of days, showcasing our #NanoKnife #IRE system for #ProstateCancer, #Biobot delivering robotic precision for #ProstateDisease, and our cost-effective, quality #biopsy solutions #Urology

aquilanturology's tweet image. We are delighted to be supporting the South West Urology Annual Meeting over the next couple of days, showcasing our #NanoKnife #IRE system for #ProstateCancer, #Biobot delivering robotic precision for #ProstateDisease, and our cost-effective, quality #biopsy solutions #Urology

The next step in AR degradetors in #prostatecancer are #RIPTACS..... The "hold & kill" Moa. By Dr Armstrong at #IPCS26 @APCCC_Lugano @Silke_Gillessen @oncourologiaarg @vicare_asocia

Martin_AngelMD's tweet image. The next step in AR degradetors in #prostatecancer are #RIPTACS..... The "hold & kill" Moa.
By Dr Armstrong at #IPCS26 @APCCC_Lugano @Silke_Gillessen @oncourologiaarg @vicare_asocia

Don't Miss! The #APCCC26 Consensus Meeting focuses on real-world #ProstateCancer management. @Silke_Gillessen joins @neerajaiims to discuss the upcoming 10th aniversary meeting, Apr 30th - May 2nd, shaping how we manage advanced prostate cancer in the real world and tackling


Honored to have been invited to serve on @ASCO’s Metastatic Castration-Resistant Prostate Cancer Living Guideline Panel. Grateful for the opportunity to contribute to evidence-based guidance in prostate cancer care. #GUOnc #ProstateCancer #pcsm #MedTwitter #OncTwitter

KalantriShreyas's tweet image. Honored to have been invited to serve on @ASCO’s Metastatic Castration-Resistant Prostate Cancer Living Guideline Panel.

Grateful for the opportunity to contribute to evidence-based guidance in prostate cancer care.

#GUOnc #ProstateCancer #pcsm #MedTwitter #OncTwitter

⚠️ The timing for presenting neoadjuvant therapy in #prostatecancer by Dr Briganti while awaiting the results of Proteus could not be more appropriate @APCCC_Lugano #IPCS26 Still missing.... How to identify the responders❓ @Silke_Gillessen @oncourologiaarg @fundacion_FUCA

Martin_AngelMD's tweet image. ⚠️ The timing for  presenting neoadjuvant therapy in #prostatecancer by Dr Briganti while awaiting the results of Proteus could not be more appropriate
@APCCC_Lugano #IPCS26
Still missing.... How to identify the responders❓ @Silke_Gillessen @oncourologiaarg @fundacion_FUCA
Martin_AngelMD's tweet image. ⚠️ The timing for  presenting neoadjuvant therapy in #prostatecancer by Dr Briganti while awaiting the results of Proteus could not be more appropriate
@APCCC_Lugano #IPCS26
Still missing.... How to identify the responders❓ @Silke_Gillessen @oncourologiaarg @fundacion_FUCA
Martin_AngelMD's tweet image. ⚠️ The timing for  presenting neoadjuvant therapy in #prostatecancer by Dr Briganti while awaiting the results of Proteus could not be more appropriate
@APCCC_Lugano #IPCS26
Still missing.... How to identify the responders❓ @Silke_Gillessen @oncourologiaarg @fundacion_FUCA
Martin_AngelMD's tweet image. ⚠️ The timing for  presenting neoadjuvant therapy in #prostatecancer by Dr Briganti while awaiting the results of Proteus could not be more appropriate
@APCCC_Lugano #IPCS26
Still missing.... How to identify the responders❓ @Silke_Gillessen @oncourologiaarg @fundacion_FUCA

❓ Do you think clinicians should continue imaging surveillance for radiographic progression despite stable PSA in advanced #prostatecancer? 🔎 See what a recent analysis discovered about the use of periodic surveillance imaging: buff.ly/HEoTnt0


Generative Artificial Intelligence for Medical Summarization in Prostate Cancer: Comparative Evaluation by Physicians and Patient Advocates—A Pilot Study. Read the full article. bit.ly/4cXbLC2 #ProstateCancer #pcsm


📢 Great starting!! Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia

Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia
Martin_AngelMD's tweet image. 📢 Great starting!!
Dr. Charles Sawyers addressing in the #AACR oppening lecture in transition from adenoCa to NEC in #prostatecancer at #IPCS26 @APCCC_Lugano @Silke_Gillessen 🇨🇭 @oncourologiaarg @fundacion_FUCA @vicare_asocia

CAPTAIN Trial Results — by the numbers. This randomized trial enrolled 211 men with localized intermediate-risk #prostatecancer, comparing MRI-guided #TULSAprocedure to robotic prostatectomy. The data shows meaningful differences in recovery, function, and time back to life.

BuschCenter's tweet image. CAPTAIN Trial Results — by the numbers.

This randomized trial enrolled 211 men with localized intermediate-risk #prostatecancer, comparing MRI-guided #TULSAprocedure to robotic prostatectomy.

The data shows meaningful differences in recovery, function, and time back to life.

Neue Erfolgsmeldung zu mRNA-Impfstoff gegen Pankreas-Ca; Überdiagnosen von Prostata-Ca; Waldbrände erhöhen Krebsrisiko; Myokarditis und Triple-M-Syndrom nach ICI #oncology, #prostatecancer, deutsch.medscape.com/viewarticle/%C…


Starting the #IPCS26... One of the most important conference in #prostatecancer with experts around the globe 🌏 @Silke_Gillessen @APCCC_Lugano

Martin_AngelMD's tweet image. Starting the #IPCS26... One of the most important conference in #prostatecancer with experts around the globe 🌏
@Silke_Gillessen @APCCC_Lugano

ઇઝરાયલ PM નેતન્યાહુને પ્રોસ્ટેટ કેન્સર; પુરુષો માટે સાયલન્ટ ખતરો, 50 વર્ષ પછી દર વર્ષે સ્ક્રીનિંગ કરાવવું જરૂરી; લક્ષણો અને બચાવના ઉપાયો #PhysicalHealth #ProstateCancer #Cancer #Health #Lifestyle divya.bhaskar.com/cf4Z5X7KH2b


#ASCOGU26 — POSEIDON Study Adding ADT to salvage radiotherapy after prostatectomy improves survival only when PSA > 0.5 ng/mL. For early recurrence (PSA ≤ 0.5), RT alone appears sufficient. Short-term ADT (4–6 months) is adequate. #ASCO #ProstateCancer #RadiationOncology

ozdogan_md's tweet image. #ASCOGU26 — POSEIDON Study

Adding ADT to salvage radiotherapy after prostatectomy improves survival only when PSA > 0.5 ng/mL.

For early recurrence (PSA ≤ 0.5), RT alone appears sufficient.

Short-term ADT (4–6 months) is adequate.

#ASCO #ProstateCancer #RadiationOncology

⭐️Can PSMA PET augment #ProstateCancer detection?? 🔬Only one way to find out! Trial in the works via @clintbahler & Wayne Brisbane @PSMAconference 2026 @UclaUrology @IUuro @CalaisJeremie @PCFnews @PCF_Science

Adam_Weiner535's tweet image. ⭐️Can PSMA PET augment #ProstateCancer detection??

🔬Only one way to find out!

Trial in the works via @clintbahler & Wayne Brisbane

@PSMAconference 2026

@UclaUrology @IUuro @CalaisJeremie @PCFnews @PCF_Science

For #ProstateCancer, there are three types 🐢🐇🐦‍⬛

Adam_Weiner535's tweet image. For #ProstateCancer, there are three types

🐢🐇🐦‍⬛

PROSTATE CANCER IS A SPECTRUM Tortoises. Rabbits. Birds. Not all prostate cancer behaves the same way. Some tumors grow very slowly and may never cause harm. These are often lower-risk cancers, commonly referred to as Gleason 6 or Grade Group 1, and many men with this type of



Our Specialist Nurses will return on Tuesday 7 April, but there are other ways for you to get support over #Easter. 💬 There's no such thing as a silly question and we're also here to help your loved ones. ➡️ Get in touch: bit.ly/4sDXd0c #ProstateCancer l #Support

ProstateUK's tweet image. Our Specialist Nurses will return on Tuesday 7 April, but there are other ways for you to get support over #Easter. 

💬 There's no such thing as a silly question and we're also here to help your loved ones.

➡️ Get in touch: bit.ly/4sDXd0c

#ProstateCancer l #Support

So grateful to @yunroseli for bringing @ASTRO_org Pres @NehaVapiwala from @PennCancer to headline our @cityofhope GU retreat! A terrific talk on oligometastatic #prostatecancer (standing room only!) to kick off an exciting agenda w @WesleyYipMD, @charlesbnguyen, @arafflemd,

montypal's tweet image. So grateful to @yunroseli for bringing @ASTRO_org Pres @NehaVapiwala from @PennCancer to headline our @cityofhope GU retreat! A terrific talk on oligometastatic #prostatecancer (standing room only!) to kick off an exciting agenda w @WesleyYipMD, @charlesbnguyen, @arafflemd,

🚨PARP-I for #prostatecancer “In order to move to earlier stage disease, we will need to see survival benefit” Wise words from @AttardLab 1/3 of patients require a blood transfusion - have to balance these costs with clear benefits @Uroweb #EAU26 @PCFnews @urotoday

Adam_Weiner535's tweet image. 🚨PARP-I for #prostatecancer

“In order to move to earlier stage disease, we will need to see survival benefit”

Wise words from @AttardLab 

1/3 of patients require a blood transfusion - have to balance these costs with clear benefits 

@Uroweb #EAU26 @PCFnews @urotoday
Adam_Weiner535's tweet image. 🚨PARP-I for #prostatecancer

“In order to move to earlier stage disease, we will need to see survival benefit”

Wise words from @AttardLab 

1/3 of patients require a blood transfusion - have to balance these costs with clear benefits 

@Uroweb #EAU26 @PCFnews @urotoday
Adam_Weiner535's tweet image. 🚨PARP-I for #prostatecancer

“In order to move to earlier stage disease, we will need to see survival benefit”

Wise words from @AttardLab 

1/3 of patients require a blood transfusion - have to balance these costs with clear benefits 

@Uroweb #EAU26 @PCFnews @urotoday

🚨Germline and somatic alterations in #ProstateCancer Great summary by @Dolmos77 Prioritizing education on molecular alterations hugely valuable at #EAU26 @Uroweb @urotoday @UrologyTimes @PCFnews

Adam_Weiner535's tweet image. 🚨Germline and somatic alterations in #ProstateCancer 

Great summary by @Dolmos77 

Prioritizing education on molecular alterations hugely valuable at #EAU26
 
@Uroweb @urotoday @UrologyTimes @PCFnews
Adam_Weiner535's tweet image. 🚨Germline and somatic alterations in #ProstateCancer 

Great summary by @Dolmos77 

Prioritizing education on molecular alterations hugely valuable at #EAU26
 
@Uroweb @urotoday @UrologyTimes @PCFnews

🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨 @NEJM New phase 3 RCT (PATCH/STAMPEDE-1) 🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360) ✅ 87.1% vs 85.9% 3-yr MFS 🌡️ Way fewer hot flashes (44% vs 89%) 🦴

Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴
Adam_Weiner535's tweet image. 🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM  New phase 3 RCT (PATCH/STAMPEDE-1) 

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS 
🌡️ Way fewer hot flashes (44% vs 89%) 
🦴

ONE WEEK TO GO ⤵️ Join our FREE online webinar, led by our Specialist Nurses, about living well during and after #Radiotherapy for #ProstateCancer. 🗓️ Tuesday 21 April ⏰ 6-7:30pm ➡️ Book your spot: bit.ly/4m1jKBY

ProstateUK's tweet image. ONE WEEK TO GO ⤵️ 

Join our FREE online webinar, led by our Specialist Nurses, about living well during and after #Radiotherapy for #ProstateCancer.

🗓️ Tuesday 21 April
⏰ 6-7:30pm
➡️ Book your spot: bit.ly/4m1jKBY

🚨Dual PET for treatment naive #prostatecancer🚨 The combination of PSMA and FAPI-based PET can localize more metastatic and primary cancers compared with PSMA alone 👉 Still need to determine who would benefit most from an additional PET @Uroweb @UrologyTimes #EAU26

Adam_Weiner535's tweet image. 🚨Dual PET for treatment naive #prostatecancer🚨

The combination of PSMA and FAPI-based PET can localize more metastatic and primary cancers compared with PSMA alone

👉 Still need to determine who would benefit most from an additional PET

@Uroweb @UrologyTimes #EAU26
Adam_Weiner535's tweet image. 🚨Dual PET for treatment naive #prostatecancer🚨

The combination of PSMA and FAPI-based PET can localize more metastatic and primary cancers compared with PSMA alone

👉 Still need to determine who would benefit most from an additional PET

@Uroweb @UrologyTimes #EAU26

For the first time ever, we have a TRIPLE header day ahead of us 🏃 Good luck to everyone taking on @LLHalf, @BrightonMarathn and @ParisMarathon tomorrow. 💙 Thank you for helping us work towards a future where no man dies from #ProstateCancer. #Marathon l #HalfMarathon

ProstateUK's tweet image. For the first time ever, we have a TRIPLE header day ahead of us 🏃

Good luck to everyone taking on @LLHalf, @BrightonMarathn and @ParisMarathon tomorrow.

💙 Thank you for helping us work towards a future where no man dies from #ProstateCancer.

#Marathon l #HalfMarathon

Do you have questions about #Radiotherapy? 💭 Join our FREE online webinar, led by our Specialist Nurses, about living well during and after radiotherapy for #ProstateCancer. 🗓️ Tuesday 21 April ⏰ 6-7:30pm ➡️ Book your spot: bit.ly/4m1jKBY

ProstateUK's tweet image. Do you have questions about #Radiotherapy? 💭

Join our FREE online webinar, led by our Specialist Nurses, about living well during and after radiotherapy for #ProstateCancer.

🗓️ Tuesday 21 April
⏰ 6-7:30pm
➡️ Book your spot: bit.ly/4m1jKBY

Have you discovered The Prostate Health Hub yet? 🤔 It's our welcoming online space for anyone affected by #ProstateCancer. This isn’t a science journal. It’s a place for relatable stories, health and wellbeing tips and so much more. ➡️ Sign up today: bit.ly/4stBuHC

ProstateUK's tweet image. Have you discovered The Prostate Health Hub yet? 🤔

It's our welcoming online space for anyone affected by #ProstateCancer.

This isn’t a science journal. It’s a place for relatable stories, health and wellbeing tips and so much more.

➡️ Sign up today: bit.ly/4stBuHC

🚨Prelim data from Weiner Lab on biologic correlates with PSMA in localized #ProstateCancer Much more to come on our lab’s major work! @PSMAconference @CSCancerCenter @PCFnews @PCF_Science

Adam_Weiner535's tweet image. 🚨Prelim data from Weiner Lab on biologic correlates with PSMA in localized #ProstateCancer

Much more to come on our lab’s major work!

@PSMAconference @CSCancerCenter @PCFnews  @PCF_Science

Can CAR T finally crack #mCRPC? Investigational all-in-one CAR T-Cell platform for #ProstateCancer. @NourShobaki @PennMedicine joins @zklaassen_md @GACancerCenter to discuss an all‑in‑one CAR T platform targeting STEAP2 and locally secreting PSMA‑CD28 bispecifics to turn

urotoday's tweet image. Can CAR T finally crack #mCRPC?
Investigational all-in-one CAR T-Cell platform for #ProstateCancer. @NourShobaki @PennMedicine joins @zklaassen_md @GACancerCenter to discuss an all‑in‑one CAR T platform targeting STEAP2 and locally secreting PSMA‑CD28 bispecifics to turn

🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides 🧬 Digital path in @Nature_NPJ 🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 💊Luminal B → predicts hormone therapy response ⚠️Luminal B & LP → flags aggressive pathology at surgery ⭐️Cheaper. Faster.

Adam_Weiner535's tweet image. 🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides

🧬 Digital path in @Nature_NPJ  
🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 
💊Luminal B → predicts hormone therapy response
⚠️Luminal B & LP → flags aggressive pathology at surgery

⭐️Cheaper. Faster.
Adam_Weiner535's tweet image. 🔬 AI predicts #prostatecancer molecular subtypes directly from H&E biopsy slides

🧬 Digital path in @Nature_NPJ  
🎯 AUC 0.863 (PAM50) | 0.81 (PSC) 
💊Luminal B → predicts hormone therapy response
⚠️Luminal B & LP → flags aggressive pathology at surgery

⭐️Cheaper. Faster.

This is what football’s all about 💙 Danny was diagnosed with incurable #ProstateCancer in 2021. This #NonLeagueDay, @OssettUnited centred the day around him, making him assistant manager for their game. ➡️ Read more: bit.ly/4c3IjJX @NonLeagueDayUK

ProstateUK's tweet image. This is what football’s all about 💙

Danny was diagnosed with incurable #ProstateCancer in 2021.

This #NonLeagueDay, @OssettUnited centred the day around him, making him assistant manager for their game.

➡️ Read more: bit.ly/4c3IjJX

@NonLeagueDayUK

Considerations for managing patients as they progress to castration-resistant #ProstateCancer. @TiansterZhang @UTSWMedCenter joins @zklaassen_md @GACancerCenter outlining management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant

urotoday's tweet image. Considerations for managing patients as they progress to castration-resistant #ProstateCancer. @TiansterZhang @UTSWMedCenter joins @zklaassen_md @GACancerCenter outlining management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant

Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy academic.oup.com/oncolo/advance… This study analyzed 22,061 advanced #ProstateCancer cases to evaluate homologous recombination deficiency (HRD) signatures and BRCA2

APCCC_Lugano's tweet image. Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy

academic.oup.com/oncolo/advance…

This study analyzed 22,061 advanced #ProstateCancer cases to evaluate homologous recombination deficiency (HRD) signatures and BRCA2

Loading...

Something went wrong.


Something went wrong.